Patients Must Have H3 K27M Tumor Mutation for Clinical Trial with ONC201

Andrew Chi, MD, PhD at NYU Langone Medical Center Explains How Patients Must Have H3 K27M Tumor Mutation for Clinical Trial with ONC201. Clinical Trial: ONC201 in Adults With Recurrent H3 K27M High-grade Glioma.